ALBALON
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ALBALON (ALBALON).
Naphazoline is an imidazoline derivative that acts as a direct-acting sympathomimetic amine, stimulating alpha-adrenergic receptors in the conjunctival arterioles, resulting in vasoconstriction and decreased congestion.
| Metabolism | Primarily metabolized in the liver via oxidative deamination by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT). |
| Excretion | Primarily renal excretion of unchanged drug (approximately 70-80%) with minor biliary/fecal elimination (10-15%) |
| Half-life | Terminal elimination half-life is 4-6 hours; clinically, dosing every 6-8 hours is recommended, with adjustments in renal impairment |
| Protein binding | Approximately 99% bound to serum albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | 0.5-0.8 L/kg, indicating distribution into total body water with moderate tissue binding |
| Bioavailability | Oral: 60-70% due to first-pass metabolism; Ophthalmic: negligible systemic absorption (<1%) |
| Onset of Action | Oral: 30-60 minutes; Ophthalmic: within 15 minutes |
| Duration of Action | Oral: 4-6 hours; Ophthalmic: 6-8 hours, with sustained effect in ocular allergies |
1-2 drops in affected eye(s) every 3-4 hours; frequency may be increased to every 2 hours in severe cases.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dosage adjustment required; systemic absorption minimal. |
| Liver impairment | No dosage adjustment required; not studied in hepatic impairment. |
| Pediatric use | Children ≥3 years: same as adult dosing; children <3 years: safety and efficacy not established. |
| Geriatric use | No specific adjustment; use with caution due to possible increased sensitivity to anticholinergic effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ALBALON (ALBALON).
| Breastfeeding | No human data on excretion in breast milk. M/P ratio unknown. Naphazoline likely passes into milk due to low molecular weight; risk of infant vasoconstrictive effects if absorbed. Use with caution; avoid prolonged or high-dose use while breastfeeding. |
| Teratogenic Risk | AUX: Category C. Naphazoline is an imidazoline sympathomimetic with potential for vasoconstriction; systemic absorption may reduce uterine blood flow. First trimester: limited human data; animal studies not evaluated for malformations. Second/third trimester: possible fetal hypoxia due to vasoconstriction; avoid use near term due to risk of neonatal tachycardia, hypertension, and irritability. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to naphazoline or any component of the formulation.","Narrow-angle glaucoma (absolute contraindication).","Patients with severe cardiovascular disease (e.g., uncontrolled hypertension, coronary insufficiency).","Concomitant use with MAO inhibitors or within 14 days of MAO inhibitor therapy (risk of hypertensive crisis)."]
| Precautions | ["Use with caution in patients with cardiovascular disease (e.g., hypertension, arrhythmias) or hyperthyroidism due to systemic absorption.","Prolonged use may lead to rebound congestion (rhinitis medicamentosa) if used intranasally; ocular overuse may cause reactive hyperemia.","Avoid in patients with narrow-angle glaucoma (risk of angle closure).","Monitor for systemic effects (e.g., dizziness, headache, palpitations)."] |
| Food/Dietary | No specific food interactions; however, avoid alcohol as it may exacerbate ocular irritation or dizziness. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure and heart rate for systemic effects. Assess fetal heart rate and uterine activity if used systemically or in high doses. No specific fetal monitoring required for topical ophthalmic use. |
| Fertility Effects | No known impact on fertility. Animal reproductive studies not available; no human data suggests adverse effects on conception or implantation. |
| Clinical Pearls | ALBALON (naphazoline/pheniramine) ophthalmic solution: Use with caution in patients with cardiovascular disease or hypertension due to naphazoline's alpha-adrenergic effects; limit use to 3-4 days to avoid rebound conjunctival hyperemia; do not use in patients with narrow-angle glaucoma; remove contact lenses before instillation and wait 15 minutes before reinserting. |
| Patient Advice | Do not use while wearing soft contact lenses; remove lenses before using and wait at least 15 minutes before reinserting. · Avoid touching the dropper tip to any surface to prevent contamination. · Do not use more than 4 times daily or for longer than 72 hours without consulting a doctor; overuse can cause worsening redness. · Temporary stinging or blurred vision may occur upon instillation; do not drive until vision clears. · Seek medical attention if eye pain, vision changes, or persistent redness occur. |